Bulletin
Investor Alert

Jan. 24, 2022, 7:27 a.m. EST

Merck says FDA wants more information about its experimental cough treatment

Shares of Merck & Co. Inc. (NYS:MRK) gained 0.4% in premarket trading on Monday after the company said the Food and Drug Administration requested additional information about its experimental cough treatment. The regulator issued a complete response letter asking for more data about the measurement of efficacy for gefapixant, Merck's investigational therapy for refractory or unexplained chronic cough. Merck also said Monday that gefapixant had received regulatory approval in Japan, where it is now called Lyfnua. Merck's stock is up 4.3% so far this year, while the S&P 500 (S&P:SPX) tumbled 7.7%.

Link to MarketWatch's Slice.